InvestorsHub Logo
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

Re: bellweather1 post# 267

Friday, 06/11/2010 7:25:24 AM

Friday, June 11, 2010 7:25:24 AM

Post# of 80490

Amid all this share price turmoil, I'm wondering if anyone has a strong opinion on the approval timeline for 113.


Regarding Ariad's ALK inhibitor AP113, the timing is in many ways dependent on what Pfizer does with crizotinib. I do think it's interesting that the one AP113 slide Harvey showed in yesterday's presentation showed how effective AP113 was against ALK mutations versus crizotinib.

Reading the tea leaves, perhaps Ariad's easiest path to approval is to take an approach similar to the one they're using with AP534 and BCR-ABL by focusing initial on patients who become resistant to the first-line therapy (assuming crizotinib get approved in NSCLC). I'm not sure how big the market is but Pfizer estimates that ALK gene alterations are considered a key driver in around 45000 newly diagnosed NSCLC patients.

Don


Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.